9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)

Authors :: Celine Pallaud
Martin Reck
Vera Gorbunova
M. Jonnaert
Tony Mok
Chong-Jen Yu
O. Burdaeva
E. Juhasz
B. Szima
Paul Delmar
Source :: European Journal of Cancer. 47:S592
Publication Year :: 2011
Publisher :: Elsevier BV, 2011.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
First line
Carboplatin/paclitaxel
Carboplatin/Gemcitabine
Internal medicine
medicine
In patient
Biomarker Analysis
business
Recurrent Non-Squamous Non-Small Cell Lung Cancer
medicine.drug

Full Text Access

Tools